臨床婦人科産科75巻8号

2021年08月発行

今月の臨床 エキスパートに聞く 耐性菌と院内感染―産婦人科医に必要な基礎知識

耐性菌各論―診断法と制御・治療戦略

基質拡張型βラクタマーゼ（ESBL）産生菌

著者： 松川雅則¹

所属機関： ¹滝川市立病院泌尿器科

ページ範囲：P.752 - P.758

文献概要

●クラスA βラクタマーゼが，ペニシリン以外も分解可能なものに変異している．

●世界中で増加傾向にあり，市中で糞便中にESBL産生菌を保菌している．

●病態により，カルバペネム薬を温存して治療する．

参考文献

1）Rottier WC, et al : Effects of confounders and intermediates on the association of bacteraemia caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae and patient outcome : a meta-analysis. J Antimicrob Chemother 67 : 1311-1320, 2012

2）石井良和：βラクタマーゼの機能分類．日臨微生物学会誌24 : 171-179, 2014

3）Kelly JA, et al : On the origin of bacterial resistance to penicillin : comparison of a beta-lactamase and a penicillin target. Science 231 : 1429-1431, 1986

4）Ambler RP : The structure of beta-lactamases. Philos Trans R Soc Lond B Biol Sci 289 : 321-331, 1980

5）Woerther PL, et al : Trends in human fecal carriage of extended-spectrum beta-lactamases in the community : toward the globalization of CTX-M. Clin Microbiol Rev 26 : 744-758, 2013

6）Kondratyeva K, et al : Meta-analysis of Pandemic Escherichia coli ST131 Plasmidome Proves Restricted Plasmid-clade Associations. Sci Rep 10 : 36, 2020

7）Bush K : Past and present perspectives on beta-lactamases. Antimicrob Agents Chemother 62 : e01076-18, 2018

8）Kobayashi K, et al : The third national Japanese antimicrobial susceptibility pattern surveillance program : bacterial isolates from complicated urinary tract infection patients. J Infect Chemother 26 : 418-428, 2020

9）Nakane K, et al : Long-term colonization by bla（CTX-M）-harboring Escherichia coli in healthy Japanese people engaged in food handling. Appl Environ Microbiol 82 : 1818-1827, 2016

10）山本詩織，他：基質特異性拡張型βラクタマーゼ（ESBL）産生菌に関わる最近の動向とその拡散に関する考察．食衛誌58 : 1-11, 2017

11）Komatsu Y, et al : Molecular epidemiology and clinical features of extended-spectrum beta-lactamase- or carbapenemase-producing Escherichia coli bacteremia in Japan. PLoS One 13 : e0202276, 2018

12）Goyal D, et al : Risk factors for community-acquired extended-spectrum beta-lactamase-producing enterobacteriaceae infections-a retrospective study of symptomatic urinary tract infections. Open Forum Infect Dis 6 : ofy357, 2019

13）Larramendy S, et al : Risk factors of extended-spectrum beta-lactamases-producing escherichia coli community acquired urinary tract infections : a systematic review. Infect Drug Resist 13 : 3945-3955, 2020

14）Karanika S, et al : Fecal colonization with extended-spectrum beta-lactamase-producing Enterobacteriaceae and risk factors among healthy individuals : a systematic review and metaanalysis. Clin Infect Dis 63 : 310-318, 2016

15）Jalilian N, et al : Colonisation with extended-spectrum beta-lactamase-producing Enterobacteriaceae in pregnant/post-partum women : systematic review and meta-analysis. J Glob Antimicrob Resist 19 : 338-347, 2019

16）Goodman KE, et al : A clinical decision tree to predict whether a bacteremic patient is infected with an extended-spectrum beta-Lactamase-producing organism. Clin Infect Dis 63 : 896-903, 2016

17）Bulabula ANH, et al : Maternal colonization or infection with extended-spectrum beta-lactamase-producing Enterobacteriaceae in Africa : a systematic review and meta-analysis. Int J Infect Dis 64 : 58-66, 2017

18）Nanayakkara D, et al : Maternal vaginal colonization with selected potential pathogens of neonatal sepsis in the era of antimicrobial resistance, a single center experience from Sri Lanka. BMC Infect Dis 18 : 351, 2018

19）Foessleitner P, et al : Vaginal colonization of extended-spectrum beta-lactamase-producing bacteria during pregnancy : an observational study. Eur J Obstet Gynecol Reprod Biol 246 : 86-89, 2020

20）Denkel LA, et al : The mother as most important risk factor for colonization of very low birth weight（VLBW） infants with extended-spectrum beta-lactamase-producing Enterobacteriaceae（ESBL-E）. J Antimicrob Chemother 69 : 2230-2237, 2014

21）Danino D, et al : Mother-to-child transmission of extended-spectrum-beta-lactamase-producing Enterobacteriaceae. J Hosp Infect 100 : 40-46, 2018

22）Rettedal S, et al : Extended-spectrum beta-lactamase-producing Enterobacteriaceae among pregnant women in Norway : prevalence and maternal-neonatal transmission. J Perinatol 35 : 907-912, 2015

23）Neemann K, et al : Neonatal outcomes associated with maternal recto-vaginal colonization with extended-spectrum beta-lactamase producing Enterobacteriaceae in Nigeria : a prospective, cross-sectional study. Clin Microbiol Infect 26 : 463-469, 2020

24）Armand-Lefevre L, et al : Emergence of imipenem-resistant gram-negative bacilli in intestinal flora of intensive care patients. Antimicrob Agents Chemother 57 : 1488-1495, 2013

25）McLaughlin M, et al : Correlations of antibiotic use and carbapenem resistance in enterobacteriaceae. Antimicrob Agents Chemother 57 : 5131-5133, 2013

26）Rodríguez-Baño J, et al : Treatment of infections caused by extended-spectrum-beta-lactamase-, AmpC-, and carbapenemase-producing Enterobacteriaceae. Clin Microbiol Rev 31 : e00079-17, 2018

27）Harris PNA, et al : Effect of piperacillin-tazobactam vs meropenem on 30-day mortality for patients with E coli or Klebsiella pneumoniae bloodstream infection and ceftriaxone resistance. JAMA 320 : 984-999, 2018

28）Karaiskos I, et al : Carbapenem-sparing strategies for ESBL producers : When and How. Antibiotics（Basel）9 : 61, 2020

29）Fukuchi T, et al : Cefmetazole for bacteremia caused by ESBL-producing enterobacteriaceae comparing with carbapenems. BMC Infect Dis 16 : 427, 2016

30）Kaye KS, et al : Fosfomycin for injection（ZTI-01）versus piperacillin-tazobactam for the treatment of complicated urinary tract infection including acute pyelonephritis : ZEUS, a phase 2/3 randomized trial. Clin Infect Dis 69 : 2045-2056, 2019

31）Nicolle LE, et al : Clinical practice guideline for the management of asymptomatic bacteriuria : 2019 update by the Infectious Diseases Society of America. Clin Infect Dis 68 : e83-e110, 2019

32）Kazemier BM, et al : Maternal and neonatal consequences of treated and untreated asymptomatic bacteriuria in pregnancy : a prospective cohort study with an embedded randomised controlled trial. Lancet Infect Dis 15 : 1324-1333, 2015

33）岩城一博．薬剤耐性菌を考慮した尿路感染症の抗菌化学療法―産婦人科医の立場から―．日化療会誌63 : 6, 2015

34）Martinez-Martinez L, et al : In vivo selection of porin-deficient mutants of Klebsiella pneumoniae with increased resistance to cefoxitin and expanded-spectrum-cephalosporins. Antimicrob Agents Chemother 40 : 342-348, 1996

35）Matsumura Y, et al : Multicenter retrospective study of cefmetazole and flomoxef for treatment of extended-spectrum-beta-lactamase-producing Escherichia coli bacteremia. Antimicrob Agents Chemother 59 : 5107-5113, 2015

36）Palacios-Baena ZR, et al : Development and validation of the INCREMENT-ESBL predictive score for mortality in patients with bloodstream infections due to extended-spectrum-beta-lactamase-producing Enterobacteriaceae. J Antimicrob Chemother 72 : 906-913, 2017

37）一般社団法人日本環境感染学会多剤耐性菌感染制御委員会 : 多剤耐性グラム陰性菌感染制御のためのポジションペーパー．環境感染32 : 29, 2017

38）Jalalzai W, et al : Cessation of screening for intestinal carriage of extended-spectrum beta-lactamase-producing Enterobacteriaceae in a low-endemicity intensive care unit with universal contact precautions. Clin Microbiol Infect 24 : 429.e7-429.e12, 2018